Bruker (BRKR) Tops Q4 EPS by 2c; offers guidance

Bruker (NASDAQ: BRKR) reported Q4 EPS of $0.76, $0.02 better than the analyst estimate of $0.74. Revenue for the quarter came in at $979.6 million versus the consensus estimate of $962.38 million.

GUIDANCE:

Bruker sees FY2025 EPS of $2.67-$2.72, versus the consensus of $2.68. Bruker sees FY2025 revenue of $3.47-3.54 million, versus the consensus of $3.57 million.

For earnings history and earnings-related data on Bruker (BRKR) click here.

You May Also Be Interested In

• Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
• Stardust Power (SDST) Tops Q2 EPS by 1c